Overview

* Vicarious Surgical ( RBOT/WS ) Q3 adjusted EPS beats analyst expectations

* Operating expenses decreased 35% yr/yr in Q3 2025

* Company raised $5.9 mln in direct offering to support operations

Outlook

* Company expects full year 2025 cash burn of approximately $50 mln

Result Drivers

* COST REDUCTIONS - Operating expenses decreased 35% yr/yr due to reductions in R&D, G&A, and sales and marketing expenses

* CAPITAL DISCIPLINE - CEO focuses on reducing burn rate while keeping development timelines on track

* FUNDRAISING - Co raised $5.9 mln in direct offering to support operations and goals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat -$1.91 -$2.33

Adjusted (3

EPS Analysts

)

Q3 EPS -$1.86

Q3 Beat -$11.30 -$14.43

Adjusted mln mln (3

Net Analysts

Income )

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Vicarious Surgical Inc ( RBOT/WS ) is $10.00, about 54.3% above its November 11 closing price of $4.57

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)